Skip navigation
Watchlist Sponsored By :

Current DateTime: 07:33:34 09 Jul 2009
LinksList Documentid: 24355697
  • Highest Grossing Movies

      What are the highest grossing movies of all time, adjusted for inflation? Click ahead to find out!

  • Most Expensive Places To Live

      Each year, Mercer Consulting assembles its ranking of the most expensive places to live. Mercer compiles information from 143 cities worldwide.

  • Recession-Resistant US Cities

      Some cities have been hit much harder than others during the recession. Here are the metro areas faring the best.


Current DateTime: 07:33:34 09 Jul 2009
LinksList Documentid: 24890560
  • Boom, Bust and Blame

      The inside story of the economic crisis that has gripped the entire world.

  • E3: Gaming's Cutting Edge

      North America's premier computer and video game trade show draws tens of thousands of professionals to experience the future of interactive entertainment.

  • The Fall of GM

      A look into the fall of General Motors as the automaker heads toward bankruptcy and an effective nationalization.

Avandia Study Results Were Leaked Early to Glaxo
By: Mike Huckman,, CNBC Pharmaceuticals Reporter | 30 Jan 2008 | 12:46 PM ET
Text Size

The wall between a prestigious medical journal and a major drug company may have been shattered.
GlaxoSmithKline Avandia
Alastair Grant / AP
GlaxoSmithKline headquarters in London.

The scientific journal Nature reported today that a peer-reviewer for The New England Journal of Medicine leaked key study results on GlaxoSmithKline's diabetes drug Avandia to the company weeks before they were published.

Steven Haffner with the University of Texas Health Science Center in San Antonio faxed the study to a Glaxo [GSK  Loading...      ()   ] employee he had worked with on an earlier Avandia study.

Haffner told Nature, "Why I sent it is a mystery. I don't really understand it. I wasn't feeling well. It was bad judgment. I've got a considerable amount of money. I didn't do it to raise my income or anything like that."

Today, Senator Chuck Grassley, the ranking member of the Senate Finance Committee, sent this letter inquiring about the leak to Glaxo's top U.S. executive.

The study in question--an analysis of many clinical trials--showed that Avandia may increase the risk of heart attacks. UK-based Glaxo's stock plummeted when the results were released May 21.

The Food and Drug Administration put a stiff warning on Avandia's label over the findings.

A Glaxo spokesperson told Nature that the inside knowledge that the company had about the study's pending publication "added an additional sense of urgency" to swiftly get the interim results of a more favorable Glaxo-sponsored study published in NEJM.

CNBC's Pharmaceutical Insider:

Peer-reviewers who break confidentiality rules are typically banned from doing future reviews and writing articles or editorials.

The Glaxo employee who received the fax is the senior director of the company's Metabolism Development Center. A Glaxo spokesperson said Haffner sent the study to the employee to get his take on it, but the company told Haffner it couldn't help him.

The spokesperson says the Glaxo executive "didn't do anything wrong."

© 2009 CNBC.com
Tools:
Print EmailAdd This share icon


Current DateTime: 02:05:32 09 Jul 2009
LinksList Documentid: 29778428

Current DateTime: 01:00:15 09 Jul 2009
LinksList Documentid: 29779196

Current DateTime: 05:04:05 09 Jul 2009
LinksList Documentid: 29779199

Current DateTime: 01:02:31 09 Jul 2009
LinksList Documentid: 29779198
CNBCCNBC
About CNBC  |  Site Map  |  Privacy Policy  |  Terms of Service  |  Video Reprints  |  Advertise  |  Help  |  Contact
Partners: AOL Money  |  BloggingStocks.com
CNBC is a Division of NBC Universal
  Data is a real-time snapshot *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
Thomson ReutersThomson Reuters